Meredith Berger, MD
Endocrinology, Diabetes & Metabolism · Midlothian, VANPI 1831181734
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 56.9% of the total. Reporting peaked in 2019 at $18,419 and has fallen 88.6% since, to $2,099 in 2025. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 765 payments — averaging $41.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$18K
- Lilly USA, LLC$2K
- Amgen$1K
- Novo Nordisk$1K
- Abbott$812
- Insulet Corporation$720
- plus $8K from 54 others
What the payments were for
- Speaking & faculty fees$16,87453%
- Food & beverage$14,66446%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$12,438
- TOUJEO$4,537
- EVENITY$244
- Prolia$121
- INTELLIS ADAPTIVESTIM$103
How this compares
$31,600 in reported general payments places this provider in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $107,635 |
| Somatuline DepotLanreotide Acetate | 13 | $105,347 |
| JardianceEmpagliflozin | 86 | $101,333 |
| SynthroidLevothyroxine Sodium | 890 | $59,004 |
| MounjaroTirzepatide | 38 | $58,410 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $56,948 |
| JanuviaSitagliptin Phosphate | 37 | $46,164 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $30,529 |
| TrulicityDulaglutide | 14 | $27,045 |
| Humalog Kwikpen U-100Insulin Lispro | 50 | $23,921 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $22,717 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $22,603 |
| HumalogInsulin Lispro | 59 | $20,347 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $17,478 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $12,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,154 | $113,49583 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,575 | $107,812138 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $19 | $105,34713 claims |
| Boehringer IngelheimJardiance | $445 | $101,33386 claims |
| AbbVieSynthroid | $396 | $59,004890 claims |
| MerckJanuvia | $195 | $46,16437 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $17,985 | $24,58453 claims |
| PfizerLevoxyl | $141 | $9,986247 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $576 | $9,769930 claims |
| IBSA Pharma Inc.Tirosint | $449 | $3,74422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Midlothian
- Samamtha HudsonMidlothian$372K
- Ben PhillipsMidlothian$99K
- Christina WagnerMidlothian$8K
- Matthew LaroeMidlothian$7K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Elias SirajNorfolk$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.